With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671

Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.

Related Keywords

Stanford University ,California ,United States ,Chicago ,Illinois ,Stanford ,American ,Tezepelumab Tezspire ,Heather Wakelee ,Heathera Wakelee ,Astrazeneca ,American Society Of Clinical Oncology ,Institute In Stanford ,Amgen ,Stanford University School ,Deputy Director ,Stanford Cancer ,Pharmacy Times ,Clinical Oncology ,Annual Meeting ,